Coronary Artery Restenosis in Women by History of Preeclampsia.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
20 09 2022
Historique:
pubmed: 9 9 2022
medline: 23 9 2022
entrez: 8 9 2022
Statut: ppublish

Résumé

Background A history of preeclampsia is associated with increased risk of coronary artery disease and experimental evidence suggests that a history of preeclampsia also increases the risk of restenosis. However, the extent to which a history of preeclampsia is associated with risk of restenosis after percutaneous coronary intervention in women is unknown. Methods and Results We included 6065 parous women aged ≤65 years with first percutaneous coronary intervention on 9452 segments 2006 to 2017, linking nationwide data on percutaneous coronary intervention and delivery history in Sweden. Main outcomes were clinical restenosis and target lesion revascularization within 2 years. We accounted for segment-, procedure-, and patient-related potential predictors of restenosis in proportional hazards regression models. Restenosis occurred in 345 segments (3.7%) and target lesion revascularization was performed on 383 patients (6.3%). A history of preeclampsia was neither significantly associated with risk of restenosis (predictor-accounted hazard ratio [HR], 0.71 [95% CI, 0.41-1.23]) nor target lesion revascularization (0.74 [95% CI, 0.51-1.07]) compared with a normotensive pregnancy history. When term and preterm preeclampsia were investigated separately, segments in women with a history of term preeclampsia had a lower risk of restenosis (predictor-accounted HR, 0.45 [95% CI, 0.21-0.94]). A history of preeclampsia was not significantly associated with death by any cause within 2 years of the index procedure (predictor-accounted HR 1.06, [95% CI, 0.62-1.80]). Conclusions A history of preeclampsia was not associated with increased risk of restenosis but instead some evidence pointed to a decreased risk. To facilitate future studies and allow for replication, concomitant collection of data on pregnancy complication history and percutaneous coronary intervention outcomes in women is warranted.

Identifiants

pubmed: 36073639
doi: 10.1161/JAHA.122.026287
pmc: PMC9683658
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e026287

Références

Hypertension. 2014 Jul;64(1):23-5
pubmed: 24752433
Circulation. 2021 Jun;143(22):2155-2165
pubmed: 33823606
J Thorac Dis. 2016 Oct;8(10):E1150-E1162
pubmed: 27867580
J Am Coll Cardiol. 2018 Apr 17;71(15):1676-1695
pubmed: 29650125
Circulation. 2019 Sep 24;140(13):1050-1060
pubmed: 31545680
Hypertension. 2020 Jul;76(1):167-175
pubmed: 32475315
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Reprod Sci. 2010 Jul;17(7):643-52
pubmed: 20360595
Circ Res. 2019 Mar 29;124(7):1094-1112
pubmed: 30920918
Am J Obstet Gynecol. 2016 Jan;214(1):106.e1-106.e14
pubmed: 26283454
Curr Cardiovasc Risk Rep. 2019;13(7):
pubmed: 32864034
Eur Heart J. 2018 Jul 7;39(26):2460-2468
pubmed: 29931092
Circulation. 2015 Sep 29;132(13):1234-42
pubmed: 26391409
CMAJ. 2021 Sep 20;193(37):E1448-E1458
pubmed: 34544783
N Engl J Med. 2004 Feb 12;350(7):672-83
pubmed: 14764923
JACC Cardiovasc Interv. 2011 Aug;4(8):896-904
pubmed: 21851905
J Am Coll Cardiol. 2009 May 5;53(18):1660-7
pubmed: 19406341
J Am Coll Cardiol. 2017 May 2;69(17):2212-2241
pubmed: 28291663
Eur Heart J. 2012 Mar;33(5):606-13
pubmed: 22232428
J Am Coll Cardiol. 2020 Sep 29;76(13):1521-1531
pubmed: 32972528
Hypertension. 2014 Jul;64(1):165-71
pubmed: 24752434
Hypertension. 2015 Apr;65(4):863-70
pubmed: 25712723
J Am Coll Cardiol. 2020 Apr 14;75(14):1631-1640
pubmed: 32273029
BMJ. 2019 Jul 15;366:l2381
pubmed: 31307997
Circ Cardiovasc Interv. 2019 Aug;12(8):e007023
pubmed: 31345066
Scand J Soc Med. 1990 Jun;18(2):143-8
pubmed: 2367825
Circ Res. 2016 Jun 10;118(12):1930-9
pubmed: 27073015
J Obstet Gynaecol Res. 2015 Dec;41(12):1877-83
pubmed: 26486233
Placenta. 2014 Feb;35 Suppl:S20-5
pubmed: 24477207
Am J Cardiol. 2017 Jan 15;119(2):210-216
pubmed: 27816119
Dis Markers. 2017;2017:9548612
pubmed: 28484288
Circ Cardiovasc Qual Outcomes. 2016 Feb;9(2 Suppl 1):S16-25
pubmed: 26908855

Auteurs

Annie Lin (A)

Perinatal and Cardiovascular Epidemiology Lund University Diabetes Centre, Clinical Sciences Malmö, Lund University Malmö Sweden.

Moa Pehrson (M)

Perinatal and Cardiovascular Epidemiology Lund University Diabetes Centre, Clinical Sciences Malmö, Lund University Malmö Sweden.

Giovanna Sarno (G)

Department of Medical Sciences Cardiology and Uppsala Clinical Research Center, Uppsala University Uppsala Sweden.

Abigail Fraser (A)

Population Health Science, Bristol Medical School University of Bristol Bristol United Kingdom.

Janet W Rich-Edwards (JW)

Division of Women's Health Department of Medicine, Brigham and Women's Hospital and Harvard Medical School Boston MA.

Isabel Gonҫalves (I)

Department of Cardiology and Cardiovascular Research Translational Studies Clinical Sciences Malmö, Lund University Malmö Sweden.

Mats Pihlsgård (M)

Perinatal and Cardiovascular Epidemiology Lund University Diabetes Centre, Clinical Sciences Malmö, Lund University Malmö Sweden.

Simon Timpka (S)

Perinatal and Cardiovascular Epidemiology Lund University Diabetes Centre, Clinical Sciences Malmö, Lund University Malmö Sweden.
Department of Obstetrics and Gynecology Skåne University Hospital Malmö Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH